Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated response correctly asserts that the FDA label supports tirzepatide-associated thyroid C-cell tumor risk in rats, the unknown human relevance, the contraindication in patients with personal/family history of MTC or MEN 2, and that routine calcitonin/ultrasound monitoring is of uncertain value with further evaluation if calcitonin is elevated or nodules are present.
Category Scores
Accurate Statements
Section 5.1 states tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and that it is unknown whether ZEPBOUND causes thyroid C-cell tumors (including MTC) in humans.
Label 5.1
ZEPBOUND is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with MEN 2.
Label 4 (and cross-reference to 5.1)
The label discusses counseling on potential risk for MTC and informing patients of symptoms of thyroid tumors.
Label 5.1
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC.
Label 5.1
If serum calcitonin is measured and elevated, the patient should be further evaluated; thyroid nodules on exam or imaging should also be further evaluated.
Label 5.1
Section 13.1 provides additional nonclinical evidence of increased thyroid C-cell adenomas (and adenomas/carcinomas combined) in rats.
Label 13.1
Unsupported Statements
Contradictions
Important Omissions
The response does not quote or mention the label’s specific calcitonin threshold detail (e.g., calcitonin values typically >50 ng/L) or the stated uncertainty rationale related to test specificity/background thyroid disease incidence.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The response stays within label-supported statements regarding thyroid C-cell tumor risk, human uncertainty, contraindications, and monitoring guidance; any omission is minor and does not introduce an incorrect claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission of specific label details (e.g., the example calcitonin level and the detailed rationale for monitoring uncertainty).
Suggested Improvement
Include the label’s specific supportive details (e.g., typical calcitonin values >50 ng/L when elevated and the stated rationale about uncertain value due to low specificity/high background incidence) while keeping the overall summary consistent with Sections 4 and 5.1.